Trial intelligence / Profile preview

Continuous infusion versus intermittent infusion of piperacillin/tazobactam for complicated or nosocomial infection with suspected or confirmed Pseudomonas aeruginosa

2010-024606-34Phase 4Completed

Sponsor: MÂª Victoria Gil Navarro
Start: Jan 2011
Modality: Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label trial of piperacillin and tazobactam in Pseudomonal infection, Healthcare-associated infection (HAI) and Infection (2 arms), sponsored by MÂª Victoria Gil Navarro. Primary endpoint: Clinical response at end of treatment or early discontinuation. Started Jan 2011; status: completed.

Drugs

piperacillintazobactam

Conditions

Pseudomonal infectionHealthcare-associated infection (HAI)Infection

Beyond the preview

Go deeper on 2010-024606-34.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-024606-34.